I believe the long-term thesis, which includes things like leadership in GLP‑1 obesity treatments, a solid pipeline, manufacturing scale, and a great financial position, is still intact. In addition, the stock continues to be cheaply valued (even cheaper than before), and the company has navigated slowing growth followed by a CEO transition before (in 2016-2017). Perhaps history can repeat itself. $Novo-Nordisk A/S(NVO)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
